The first ever malaria vaccine candidate can reach out to the third phase of clinical testing, which was found to secure kids against this menace up to 4 years after vaccination, which would be soon available by the end of October. As per reports, the vaccine candidate RTS.S/AS01 will be able to secure a tangible amount of cases found under the category of clinical malaria especially seen in the areas of high transmission.
As per reports, the EMA (European Medicines Agency) will now be assessing the quality, safety, and efficacy of the said vaccine as per the availability of these final data. Even the veterans like Brian Greenwood, professor at the London School of Hygiene & Tropical Medicine in Britain and the WHO too have given favorable opinion, which is supposed to hit the said vaccine. This report was published in the known journal called The Lancet.
The findings even revealed that said vaccine efficacy against severe and clinical malaria was much more effective in kids rather than in the young infants, but at the same time, they have waned over time in both groups. However, if you talk about protection, it is prolonged by a booster dose, which further boost up the average amount of cases that are prevented in both children and young infants. The fact is there is not a single licensed vaccine, which is seen against malaria in the entire world.